Why the study?
Does intravenous triiodothyronine improve hemodynamic variables and decrease inotropic drug requirements in patients undergoing coronary artery bypass graft surgery?
Population
211 patients undergoing coronary artery bypass graft surgery at high risk for requiring inotropic drug support
Comparison
Intravenous infusion of triiodothyronine… vs Intravenous dopamine or placebo
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
perioperative
Authors
Loading...
Does not support intravenous triiodothyronine for hemodynamic support in CABG; reinforces avoidance of routine use and directs research elsewhere.
Does intravenous triiodothyronine improve hemodynamic variables and decrease inotropic drug requirements in patients undergoing coronary artery bypass graft surgery?
Routine use of intravenous triiodothyronine as an inotropic agent in patients undergoing coronary artery bypass graft surgery is not recommended as it does not significantly improve hemodynamics or reduce inotropic requirements.
Elliott Bennett‐Guerrero (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: